EUCTR2006-003140-27-AT进行中（未招募）不适用
Effects of non-specific Endothelin-A receptor blockade on ocular blood flow in patients with glaucoma
Department of Clinical Pharmacology0 个研究点目标入组 28 人开始时间: 2006年7月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Men and women aged over 18 years
- •- Normal findings in the medical history and physical examination unless the investigator considers an
- •abnormality to be clinically irrelevant
- •- Inclusion criteria for patients is primary open angle glaucoma defined as pathological optic disc appearance
- •and characteristic visual field loss
- •- Men and women will be included in equal parts
- •- Ametropia of less than 6 diopters and anisometropia of less than 2 diopters
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria (glaucoma patients)
- •- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- •- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- •- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with
- •distribution, metabolism or excretion of study drugs
- •- Blood donation during the previous 3 weeks
- •- Ametropy > 6 dpt
- •- Systemic treatment with, oral antikoagulation, Glibenclamid or vasoactive drugs
- •- History of IOP > 30 (untreated)
- •- Presence of intraocular pathology other than glaucoma
- •- Advanced visual field defect defined as MD >-10
- •- Presence of PEX (pseudoexfoliation) glaucoma and pigment glaucoma
- •- Ophthalmolgical surgery (including argon laser trabeculoplasty (ALT), trabeculectomy, deep sclerectomy)
- •within the last 6 months before the study
- •- Pregnancy
- •- Diabetes mellitus
- •Exclusion criteria (healthy controls)
- •- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- •- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- •- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with
- •distribution, metabolism or excretion of study drugs
- •- Blood donation during the previous 3 weeks
- •- Ametropy > 6 dpt
- •- Systemic treatment with oral anticoagulation, Glibenclamid or vasoactive drugs
- •- Pregnancy
- •- Diabetes mellitus
研究者
相似试验
进行中（未招募）
1 期
Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting - BQ-123 in CABGaorto-coronary bypass surgery in patients with coronary artery diseaseMedDRA version: 12.1Level: LLTClassification code 10011077Term: Coronary artery bypassMedDRA version: 12.1Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersMedDRA version: 12.1Level: LLTClassification code 10011090Term: Coronary artery surgeryMedDRA version: 12.1Level: LLTClassification code 10011098Term: Coronary bypassMedDRA version: 12.1Level: LLTClassification code 10049887Term: Coronary revascularisationMedDRA version: 12.1Level: LLTClassification code 10054366Term: Coronary revascularizationEUCTR2010-023552-90-ATMedizinische Universität Wien, Abteilung für Herzchirurgie36
进行中（未招募）
1 期
Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosisPortal hypertension and hepatic cirrhosisMedDRA version: 16.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 16.1Level: LLTClassification code 10009213Term: Cirrhosis of liverSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2007-005679-33-DEMedizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg
进行中（未招募）
1 期
Efficacy of Endothelin 1 receptor antagonist Bosentan in secondary Raynauds Syndrom - Bosentan1secondary Raynauds SyndromeEUCTR2004-002686-21-ATDept of Dermatology40
进行中（未招募）
1 期
Efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled clinical trial. (EDIT-CAS)CTIS2023-507782-25-00Stichting Radboud University Medical Center100
招募中
2 期
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients elevated Albuminuria: a Randomized Double Blind Cross-Over Trialdiabetic kidney disease1001265310029149diabetic nephropathyNL-OMON54022niversitair Medisch Centrum Groningen12